←Back to list

The EVERY Company

Producer of food products intended to offer animal-free proteins.
Producer of food products intended to offer animal-free proteins.
Food Products 📍 Daly City, CA Founded 2014
Current Valuation
$605M
as of 2021-Q4
PRIVATE

QL Price

$201.61M
-67% vs last round
QuantLogix's current estimate for The EVERY Company, published 2026-09-27 — below the last disclosed round of $605M (2021-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $605M 2021-Q4 weight 0.04
Secondary market print $175.45M 2026-06-27 weight 0.58
How this price has held up
No round has priced for The EVERY Company since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to The EVERY Company →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, The EVERY Company, 2026-09-27 (70bd23c855b2fc78). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is The EVERY Company going public?
No. The EVERY Company is private and has not filed to go public. There is no S-1 on file.
What is The EVERY Company's valuation in 2026?
The EVERY Company is valued at $605M as of 2021-Q4, set by its Series C ($175M, Dec 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has The EVERY Company filed an S-1?
No public S-1 is on file for The EVERY Company.
How much has The EVERY Company raised?
The EVERY Company has raised $255M in total, most recently a Series C of $175M in Dec 2021.
Is The EVERY Company publicly traded — can you buy The EVERY Company stock?
No. The EVERY Company is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for The EVERY Company on its Pre-IPO Access Desk.
How to actually get exposure to The EVERY Company →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2014
HQ
Daly City, CA
Employees
127
Total Raised
$255M
Last Round
Series C — $175M (Dec 2021)
IPO Status
private

Fundraising Status

Series C · $175M · 4y 9mo ago
privateTotal raised $255M

Secondary Market

Implied price / share
$3.96
Last round price / share
$13.66
vs last round
-71.0%
Last round price vs secondary price
Last round vs current secondary price per share$13.66Last round$3.96Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month0.0%1-year0.0%All-time-1.0%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series C$175MDec 2021—$605M

Vertical Intelligence — Biotech / Gene Therapy

No name-verified sponsor record on ClinicalTrials.gov for The EVERY Company — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.

Talent Signal

Hiring trend
▼ Hiring downtrend
0% of roles posted in last 30d
Open roles
1
via greenhouse
Product-build share
100%
engineering, research, product, design
Trajectory
tightening
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 1 of 1 open roles are research.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by month1Sep '26
Open roles by function
Open roles by functionResearch1
■ product-building   ■ go-to-market / G&A
Research Associate I (Protein Science & Analytics)
Counted from The EVERY Company's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Food ProcessingSustainabilityBiotechnologyNutrition
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.